A Look At Benzinga Pro's Most-Searched Tickers For July 9, 2019

This most-searched list is a feature included in Benzinga Pro's Newsfeed tool. It highlights stocks frequently searched by Benzinga Pro users on the platform.

1. Soliton, Inc. SOLY shares were down 4.4% to $17.63. On Monday, shares rose more than 60% on news the company will announce cellulite trial data for the 26-week period on July 15.
2. Apple Inc. AAPL shares were up 0.19% to $200.40. JPMorgan reiterated an Overweight rating on the stock and raised the price target from $233 to $239.
3. Sangamo Therapeutics, Inc. SGMO shares were down 3.6% to $11.10 after the stock rose almost 14% on Monday. The company presented data from its Phase ½ Alta study evaluating investigational SB-525 gene therapy in patients with severe hemophilia A.
4. Taronis Technologies, Inc. TRNX shares were down 20.9% to 22 cents. On Monday, the company announced record-breaking MagneGas production.
5. Camber Energy, Inc. CEI shares were up 113.8% to $4.34. Shares continued to rally following the company’s announcement on Monday that it closed the acquisition of Lineal Star Holdings.
6. Acacia Communications, Inc. ACIA shares were up 35.3% to $65 after Cisco announced it will acquire the company for $70 per share in an all-cash deal.
7. Check-Cap Ltd. CHEK shares were up 4% to $2.26. The company reported positive final results from its post-CE approval study of its C-Scan system.
8. Advanced Micro Devices, Inc, AMD shares were up 2.7% to $32.90. Nomura reiterated a Buy rating on the stock and raised the price target from $33 to $37.
9. Intra-Cellular Therapies, Inc. ITCI shares were down 2.4% to $11.43. Shares continued to drop following the release of mixed study results from two Phase 3 clinical trials evaluating lumateperone as monotherapy in the treatment of major depressive episodes associated with bipolar depression.
10. Altimmune, Inc. ALT shares were up 4% to $2.58 after the company announced its plans to acquire Spitfire Pharma. The acquisition of Spitfire Pharma will add a NASH drug candidate to the company’s existing portfolio.